Published in Medicine and Law Weekly, October 15th, 2004
The agreement allows Fresenius Medical Care worldwide exclusive rights to manufacture and market the product concept HemoQlip from OptoQ. Fresenius Medical Care will integrate the product in their dialysis machines and will use it for automatic ultra filtration control.
The agreement, which is geographically limited to worldwide markets outside of the U.S. and Canada, grants OptoQ minimum annual licensing fees for the next 3 years with the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medicine and Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.